Zentalis Pharmaceuticals, Inc.
Develops small molecule cancer drugs, led by a first-in-class oral WEE1 inhibitor for tumors.
ZNTL | US
Overview
Corporate Details
- ISIN(s):
- US98943L1070
- LEI:
- Country:
- United States of America
- Address:
- 10275 SCIENCE CENTER DRIVE, 92121 SAN DIEGO
- Website:
- https://www.zentalis.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing differentiated small molecule therapeutics that target fundamental biological pathways of cancer. The company's lead product candidate is azenosertib (ZN-c3), a potentially first-in-class and best-in-class oral WEE1 inhibitor. Azenosertib is being evaluated in multiple clinical trials as a monotherapy and in combination with other therapies for various solid tumors, including ovarian cancer and uterine serous carcinoma. The company is advancing azenosertib through late-stage, registration-intent studies and has received FDA Fast Track Designation for certain indications.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Zentalis Pharmaceuticals, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Zentalis Pharmaceuticals, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Zentalis Pharmaceuticals, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
